Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.
Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.
The National Comprehensive Cancer Network recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.
– Reported OGSIVEO™ net product revenue of $5.4 million in first partial quarter of launch following FDA approval on November 27, 2023 – – Submitted Marketing Authorization Application to...
Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.